Immunotherapy hope for rare Gene-Mutated cancers

NCT ID NCT03810339

First seen Apr 23, 2026 · Last updated Apr 25, 2026 · Updated 1 time

Summary

This study tests a drug called toripalimab, which helps the immune system fight cancer. It is for people with advanced solid tumors that have specific gene changes (POLE or POLD1 mutations) but not high microsatellite instability. About 35 adults who have not responded to standard treatments will receive the drug to see if their tumors shrink or stop growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer center of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Dalian Medical University

    RECRUITING

    Dalian, Liaoning, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.